Provided by Tiger Trade Technology Pte. Ltd.

SH PHARMA

11.540
-0.110-0.94%
Volume:1.95M
Turnover:22.51M
Market Cap:42.79B
PE:9.39
High:11.640
Open:11.600
Low:11.480
Close:11.650
52wk High:12.821
52wk Low:9.577
Shares:3.71B
HK Float Shares:919.07M
Volume Ratio:2.74
T/O Rate:0.21%
Dividend:0.47
Dividend Rate:4.05%
EPS(LYR):1.229
ROE:7.91%
ROA:2.15%
PB:0.50
PE(LYR):9.39
PS:0.13

Loading ...

Shanghai Pharmaceuticals (601607.SH) Gains Approval for Minoxidil Tincture Production

Stock News
·
Dec 05, 2025

Shanghai Pharma (02607) Releases Indicative Announcement on Extraordinary General Meeting

Bulletin Express
·
Nov 28, 2025

Shanghai Pharmaceuticals (02607) Releases Extraordinary General Meeting Notice

Bulletin Express
·
Nov 18, 2025

Shanghai Pharmaceuticals (02607) Announces Proxy Form for December 2025 EGM

Bulletin Express
·
Nov 18, 2025

SH PHARMA (02607) to Distribute Interim Dividend of RMB1.2 per 10 Shares

Stock News
·
Nov 18, 2025

Shanghai Pharmaceuticals (02607) Releases EGM Notice, Introducing Supervisory Board Abolishment and Interim Dividend Plan

Bulletin Express
·
Nov 18, 2025

Shanghai Pharmaceuticals (601607.SH): Cefuroxime Sodium for Injection and Aztreonam for Injection Pass Generic Drug Consistency Evaluation

Stock News
·
Nov 10, 2025

Shanghai Pharmaceuticals (601607.SH) Receives FDA Approval for Ticagrelor Tablets

Stock News
·
Nov 06, 2025

Shanghai Pharmaceuticals (601607.SH): Tofacitinib Citrate Sustained-Release Tablets Approved for Production

Stock News
·
Nov 06, 2025

Southbound Capital Flow Statistics (T+2) for Hong Kong Stocks | November 5

Stock News
·
Nov 05, 2025

Shanghai Pharmaceuticals (02607) Releases October 2025 Monthly Return Announcement

Bulletin Express
·
Nov 03, 2025

UBS Raises SH PHARMA (02607) Target Price to HK$15, Maintains "Buy" Rating

Stock News
·
Nov 03, 2025

Stock Track | SH PHARMA Plummets 5.11% as Q3 Net Profit Drops 38% on Higher Impairment Provisions

Stock Track
·
Oct 31, 2025

HK Stock Movement | SH PHARMA (02607) Drops Over 5% as Q3 Net Profit Falls 38.13% Due to Increased Asset Impairment Provisions

Stock News
·
Oct 31, 2025

Shanghai Pharmaceuticals (02607) Releases Third Quarter 2025 Results with Revenue Reaching RMB215.07 Billion

Bulletin Express
·
Oct 30, 2025

Shanghai Pharmaceuticals (02607) Renews Procurement Framework Agreement with Wing Fat Printing

Bulletin Express
·
Oct 30, 2025

Shanghai Pharmaceuticals (02607) Announces Interim Dividend for First Half of 2025

Bulletin Express
·
Oct 30, 2025

Shanghai Pharmaceuticals (02607) Proposes 2025 Interim Profit Distribution Plan

Bulletin Express
·
Oct 30, 2025

Shanghai Pharmaceuticals Plans to Distribute 1.2 Yuan Cash Dividend per 10 Shares

Deep News
·
Oct 30, 2025

Shanghai Pharmaceuticals (601607.SH): Pyridostigmine Bromide Sustained-Release Tablets Approved for Production

Stock News
·
Oct 28, 2025